LambdaVision is pioneering the development of protein-based artificial retinas aimed at restoring meaningful vision for individuals who are blind or have lost significant sight due to advanced retinal degenerative diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). These conditions lead to the breakdown and loss of cells in the retina, severely impacting vision. By leveraging proteins similar to the visual pigment rhodopsin, naturally found in the human eye, LambdaVision's artificial retina mimics the natural process of vision.

Operating in the biotechnology and medical device market, LambdaVision primarily serves patients suffering from severe retinal diseases. The company's business model revolves around research and development, securing funding through grants and partnerships, including significant support from NASA for advanced production processes and space-based investigations. Revenue is generated through the commercialization of their artificial retina technology, targeting healthcare providers and patients in need of vision restoration solutions.

Keywords: artificial retina, protein-based, vision restoration, retinal diseases, biotechnology, medical device, retinitis pigmentosa, age-related macular degeneration, rhodopsin, NASA funding.